Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO John W. Crowley sold 6,755 shares of the firm’s stock in a transaction on Friday, October 13th. The shares were sold at an average price of $18.41, for a total transaction of $124,359.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Lantheus Holdings, Inc. (LNTH) opened at 19.30 on Friday. Lantheus Holdings, Inc. has a 12-month low of $7.95 and a 12-month high of $19.35. The stock’s 50 day moving average is $17.71 and its 200-day moving average is $17.71. The company has a market capitalization of $720.85 million, a P/E ratio of 26.37 and a beta of 0.91.
Lantheus Holdings (NASDAQ:LNTH) last released its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.18. Lantheus Holdings had a net margin of 8.44% and a negative return on equity of 37.47%. The business had revenue of $88.83 million during the quarter, compared to analyst estimates of $80.56 million. During the same quarter in the prior year, the firm earned $0.24 earnings per share. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. Analysts anticipate that Lantheus Holdings, Inc. will post $1.12 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “John W. Crowley Sells 6,755 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/28/john-w-crowley-sells-6755-shares-of-lantheus-holdings-inc-lnth-stock.html.
Institutional investors and hedge funds have recently made changes to their positions in the stock. State of Alaska Department of Revenue purchased a new stake in shares of Lantheus Holdings in the second quarter valued at about $102,000. Municipal Employees Retirement System of Michigan purchased a new stake in shares of Lantheus Holdings in the second quarter valued at about $107,000. LS Investment Advisors LLC purchased a new stake in shares of Lantheus Holdings in the second quarter valued at about $112,000. Quantbot Technologies LP purchased a new stake in shares of Lantheus Holdings in the second quarter valued at about $117,000. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Lantheus Holdings in the second quarter valued at about $141,000. 85.10% of the stock is owned by hedge funds and other institutional investors.
Several research analysts have commented on LNTH shares. Jefferies Group LLC reissued a “buy” rating and issued a $22.00 price target (up from $18.00) on shares of Lantheus Holdings in a report on Wednesday, August 2nd. BidaskClub downgraded shares of Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 17th. Zacks Investment Research downgraded shares of Lantheus Holdings from a “buy” rating to a “hold” rating in a report on Wednesday, September 20th. Credit Suisse Group lifted their price objective on shares of Lantheus Holdings from $14.00 to $19.00 and gave the stock a “neutral” rating in a report on Wednesday, August 2nd. Finally, Cantor Fitzgerald started coverage on shares of Lantheus Holdings in a report on Monday, July 17th. They set an “overweight” rating and a $22.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $18.60.
About Lantheus Holdings
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.